A61K9/0009

METHOD FOR TARGETED INTRAPROSTATIC ADMINISTRATION OF PRX302 FOR TREATMENT OF PROSTATE CANCER
20170333521 · 2017-11-23 ·

This application relates to methods of targeted focal treatment for localized prostate cancer.

Method for Operating a Benefit Agent Delivery System Comprising Microcells Having an Electrically Eroding Sealing Layer
20230165787 · 2023-06-01 ·

A benefit agent delivery system whereby benefit agents can be delivered on demand and/or a variety of different benefit agents at different concentrations can be delivered from the same system. The benefit agent delivery system includes a microcell layer comprising a plurality of microcells, wherein the microcells are filled with a carrier and a benefit agent. The microcells include an opening, wherein the opening is spanned by a sealing layer comprising a polymer and metallic material. Application of an electric field across the microcell layer and the sealing layer results in the migration of the metallic material from the sealing layer and the creation of a porous sealing layer, allowing the benefit agent to be released from the benefit agent delivery system.

Acoustic driven drug delivery systems

The present invention provides acoustically activated liposome compositions for use as drug delivery vehicles, and to methods for drug release and drug delivery for therapeutic applications.

Mesoporous silica nanoparticles for diagnostic and therapeutic applications

A system for delivering a therapeutic agent to cell or tissue of a subject includes a mesoporous silica iron oxide nanoparticle with one or more therapeutic agents that are contained in a mesoporous silica layer of the nanoparticle and a remote radiofrequency (RF) energy source for applying RF energy to the nanoparticle effective to release the one or more therapeutic agents from the nanoparticle by mechanical tumbling and/or vibration of the nanoparticle, wherein release of the one or more therapeutic agents not caused by a hyperthermic response of the nanoparticle to the RF energy.

Pharmacotherapy of neurosystem dysfunctions
11491276 · 2022-11-08 ·

Release of a neurological drug in a targeted region of a subject's brain by a drug delivery system (DDS) is intentionally caused by the subject watching or interacting with an audio/video-based task on an electronic display. The DDS is calibrated to release the neurological drug based on a particular pH, lactate level, blood flow, temperature, magnetic field, specific molecules released by brain cells, or other physiological factors within the target region. The interactive task produces the physiological factors in the brain in specific areas of pathology for which the drug is prescribed, and limits drug delivery at areas unaffected by illness where it could disrupt normal function, causing problematic side effects and preventing dose levels optimal for target impact. Feedback from the interactive task and associated cognitive probes also can adapt the interactive task or suggest new pharmacologic agents as the degree or primary focus of brain pathology changes during the course of treatment.

DEVICES FOR APPLYING A TOPICAL TREATMENT
20220347448 · 2022-11-03 ·

A device comprising a housing having a handle end and a treatment end. The treatment end is configured to provide an antimicrobial treatment and a heat treatment. The treatment end comprises an applicator having an applicator surface for providing at least the heat treatment. The device includes a heat generation unit configured to heat the applicator surface in use, a source of antimicrobial agent, and a control unit operatively connected to at least the heat generation unit for controlling the heat generation unit. The device can be a hand-held device and used to apply topical treatment to a treatment area of a subject.

Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

SYNERGISTIC THERAPIES FOR INTERVERTEBRAL DISC DEGENERATION

A method for treating an intervertebral disc of a subject is provided, the method including delivering a growth factor to a nucleus pulposus of the intervertebral disc. At least one intra-pulposus exposed electrode surface is implanted in the nucleus pulposus. At least one extra-pulposus exposed electrode surface is implanted in a body of the subject outside the nucleus pulposus. The growth factor is supported by activating control circuitry to drive the intra-pulposus and the extra-pulposus exposed electrode surfaces to electroosmotically drive nutrient-containing fluid into the nucleus pulposus. Other embodiments are also described.

Delivery of corticosteroids through iontophoresis

Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.

Method and apparatus for improved wound healing
09789303 · 2017-10-17 ·

A pad for electrically stimulated wound healing, including a pad configured to be placed on a wound, at least one anode disposed on the pad to contact the wound, and at least one cathode disposed on the pad to contact the wound, the at least one cathode being disposed separately from the at least on anode. The pad wherein the at least one anode and the at least one cathode in contact with the wound provide a flow of electrical current in an intended direction through the wound based on the separate locations of the at least one anode and the at least one cathode.